Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Captopril
Drug ID BADD_D00354
Description Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
Indications and Usage For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.
Marketing Status Prescription; Discontinued
ATC Code C09AA01
DrugBank ID DB01197
KEGG ID D00251
MeSH ID D002216
PubChem ID 44093
TTD Drug ID D0I0EG
NDC Product Code 69292-526; 0781-8052; 51552-1072; 51407-602; 27241-162; 71335-1918; 53296-0031; 60687-315; 57721-905; 31722-143; 63673-0457; 53069-0150; 50090-4296; 0143-1171; 63629-8729; 57721-903; 71335-0826; 0904-5045; 55488-0600; 27241-163; 31722-141; 51927-0137; 63629-1338; 0143-1173; 31722-142; 0143-1172; 0781-8080; 60687-304; 51407-603; 0904-5047; 63629-8727; 0904-5046; 0904-7105; 27241-161; 0143-1174; 70518-3307; 51407-600; 63629-8728; 0781-8075; 55289-344; 69292-528; 69292-524; 0904-7106; 57721-904; 63629-8730; 31722-144; 27241-160; 57721-902; 69292-522; 51407-601; 0781-8061
Synonyms Captopril | (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline | Lopirin | SQ-14,534 | SQ 14,534 | SQ14,534 | SQ-14534 | SQ 14534 | SQ14534 | Capoten | SQ-14,225 | SQ 14,225 | SQ14,225 | SQ-14225 | SQ 14225 | SQ14225
Chemical Information
Molecular Formula C9H15NO3S
CAS Registry Number 62571-86-2
SMILES CC(CS)C(=O)N1CCCC1C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionSolute carrier family 2, facilitated glucose transporter member 2P11168Not Available9090458; 8866414; 12939321
Adverse drug reactionSolute carrier family 2, facilitated glucose transporter member 1P11166T894589090458; 8866414; 12939321; 9096453
Blood pressure decreasedKallikrein-10O43240Not Available3901042; 3544715; 6315269
Blood pressure decreasedAngiotensin-converting enzymeP12821T8257716395257; 16138565; 9270093; 10535720; 9726242; 10620209; 10880412; 8986921; 10999650
Blood pressure decreasedKininogen-1P01042T307313901042; 3544715; 6315269; 6283904
CoughB2 bradykinin receptorP30411T2371410904024; 12522467; 11699055; 15894833
LeukopeniaLysozyme CP61626T105866764221; 7184960; 7055639; 6991024; 1151072; 874088; 6490097; 6295781; 3293542
LeukopeniaBeta-glucuronidaseP08236T964136764221; 7184960; 7055639; 6991024; 1151072; 874088; 6490097; 6295781; 3293542
ProteinuriaAngiotensin-converting enzyme 2Q9BYF1T278893540694; 6761860; 3281046; 6993700
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tachypnoea22.02.01.0140.002235%Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.0070.003353%Not Available
Tongue ulceration07.14.01.003--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.002235%
Ulcer08.03.06.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.0040.002235%
Vasculitis10.02.02.006; 24.05.02.001--
Ventricular arrhythmia02.03.04.0060.000583%
Vision blurred17.17.01.010; 06.02.06.0070.002235%
Vomiting07.01.07.0030.006706%
Weight decreased13.15.01.005--
Wheezing22.03.01.0090.005589%
Tubulointerstitial nephritis20.05.02.002--Not Available
Red blood cell sedimentation rate increased13.01.03.001--Not Available
Muscle tightness15.05.03.0070.003353%Not Available
Bradyphrenia19.10.03.002; 17.03.03.0040.002235%Not Available
Protein urine present13.13.02.006--Not Available
Epigastric discomfort07.01.02.004--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Thermal burn12.05.04.001--
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.002235%Not Available
Cerebrovascular insufficiency24.04.06.004; 17.08.02.003--Not Available
Urine output increased13.13.03.002--Not Available
Antinuclear antibody positive13.06.01.003--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049--Not Available
Obstructive airways disorder22.03.01.011--Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages